<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114223</article-id><article-id pub-id-type="publisher-id">ACM-41588</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_14601920.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  乳腺癌HER2指南更新要点对判读结果的影响及HER2阳性乳腺癌的特征
  The Impact of the Update of Breast Cancer HER2 Guidelines on Interpretation Results and the Characteristics of HER2-Positive Breast Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>思雨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>魏</surname><given-names>志敏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>瑞祥</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曾</surname><given-names>满芹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>龙宵</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>董</surname><given-names>娴宁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院脊柱外科，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院病理科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1558</fpage><lpage>1565</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：比较2014版与2019版乳腺癌HER2检测指南对乳腺癌中人表皮生长因子受体2 (HER2)基因扩增与蛋白表达状态判读结果的影响及其临床意义。方法：根据2014版与2019版判读标准对青岛大学附属医院的3102例乳腺癌标本进行重新判读，并对结果异同之处进行分析。结果：1、在依据2014版及2019版标准判读的免疫组织化学(IHC)结果中，2019版判读结果为不确定的病例数减少，阴性病例数增加，经计算，两版结果差异有统计学意义(X
   <sup>&#178;</sup> = 1604.13, P &lt; 0.05)。2、在依据2014版及2019版判读的荧光原位杂交(FISH)结果中，2019版判读结果为阳性及不确定的病例数减少，阴性病例数增加，经统计学检验，两版结果差异有统计学意义(P = 0.000, P &lt; 0.05)。3、HER2阳性组和阴性组的组织学分级、肿瘤大小等临床病理学特征的差异有统计学意义。结论：HER2阳性组和阴性组的组织学分级、肿瘤大小等临床病理学特征均有显著差异(P &lt; 0.05)。采用2019版指南使乳腺癌HER2检测阴性率提高，阳性率及不确定率有所下降，应用2019版乳腺癌HER2检测指南判读结果更明确，在乳腺癌治疗方面具有更好的适用性。
    Objective: To compare the effects of the 2014 version and 2019 version of the breast cancer HER2 detection guidelines on the interpretation of human epidermal growth factor receptor 2 (HER2) gene amplification and protein expression status in breast cancer and its clinical significance. Methods: According to the interpretation standards of the 2014 and 2019 editions, 3102 breast cancer specimens from the Affiliated Hospital of Qingdao University were re-interpreted, and the similarities and differences of the results were analyzed. Results: 1. Among the results of immunohistochemistry (IHC) interpreted according to the standards of the 2014 and 2019 editions, the number of undefined cases in the 2019 edition decreased and the number of negative cases increased. After calculation, the difference between the results of the two editions was statistically significant (X
   <sup>&#178;</sup> = 1604.13, P &lt; 0.05). 2. In the fluorescence in situ hybridization (FISH) results interpreted according to the 2014 and 2019 editions, the number of positive and uncertain cases in the 2019 edition has decreased, and the number of negative cases has increased. After statistical testing, there are differences in the results of the two editions; statistical significance (P = 0.000, P &lt; 0.05). 3. There are statistically significant differences in the histological grade, tumor size and other clinicopathological characteristics between the HER2 positive group and the negative group. Conclusion: There are significant differences in the histological grade, tumor size and other clinicopathological characteristics between the HER2 positive group and the negative group (P &lt; 0.05). The 2019 version of the guidelines has increased the negative rate of breast cancer HER2 detection, and the positive rate and uncertainty rate have decreased. The application of the 2019 version of the breast cancer HER2 detection guidelines has a clearer interpretation and has better applicability in the treatment of breast cancer. 
  
 
</p></abstract><kwd-group><kwd>乳腺癌，HER2，免疫组织化学，原位杂交，指南更新, Breast Cancer</kwd><kwd> HER2</kwd><kwd> Immunohistochemistry</kwd><kwd> In Situ Hybridization</kwd><kwd> Guide Update</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：比较2014版与2019版乳腺癌HER2检测指南对乳腺癌中人表皮生长因子受体2 (HER2)基因扩增与蛋白表达状态判读结果的影响及其临床意义。方法：根据2014版与2019版判读标准对青岛大学附属医院的3102例乳腺癌标本进行重新判读，并对结果异同之处进行分析。结果：1、在依据2014版及2019版标准判读的免疫组织化学(IHC)结果中，2019版判读结果为不确定的病例数减少，阴性病例数增加，经计算，两版结果差异有统计学意义(X&#178; = 1604.13, P &lt; 0.05)。2、在依据2014版及2019版判读的荧光原位杂交(FISH)结果中，2019版判读结果为阳性及不确定的病例数减少，阴性病例数增加，经统计学检验，两版结果差异有统计学意义(P = 0.000, P &lt; 0.05)。3、HER2阳性组和阴性组的组织学分级、肿瘤大小等临床病理学特征的差异有统计学意义。结论：HER2阳性组和阴性组的组织学分级、肿瘤大小等临床病理学特征均有显著差异(P &lt; 0.05)。采用2019版指南使乳腺癌HER2检测阴性率提高，阳性率及不确定率有所下降，应用2019版乳腺癌HER2检测指南判读结果更明确，在乳腺癌治疗方面具有更好的适用性。</p></sec><sec id="s2"><title>关键词</title><p>乳腺癌，HER2，免疫组织化学，原位杂交，指南更新</p></sec><sec id="s3"><title>The Impact of the Update of Breast Cancer HER2 Guidelines on Interpretation Results and the Characteristics of HER2-Positive Breast Cancer</title><p>Siyu Wu<sup>1</sup>, Zhimin Wei<sup>1</sup>, Ruixiang Xu<sup>2</sup>, Manqin Zeng<sup>1</sup>, Longxiao Zhang<sup>1</sup>, Xianning Dong<sup>1</sup></p><p><sup>1</sup>Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Spinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/16-1572117x4_hanspub.png" /></p><p>Received: Mar. 12<sup>th</sup>, 2021; accepted: Apr. 7<sup>th</sup>, 2021; published: Apr. 15<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/16-1572117x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To compare the effects of the 2014 version and 2019 version of the breast cancer HER2 detection guidelines on the interpretation of human epidermal growth factor receptor 2 (HER2) gene amplification and protein expression status in breast cancer and its clinical significance. Methods: According to the interpretation standards of the 2014 and 2019 editions, 3102 breast cancer specimens from the Affiliated Hospital of Qingdao University were re-interpreted, and the similarities and differences of the results were analyzed. Results: 1. Among the results of immunohistochemistry (IHC) interpreted according to the standards of the 2014 and 2019 editions, the number of undefined cases in the 2019 edition decreased and the number of negative cases increased. After calculation, the difference between the results of the two editions was statistically significant (X&#178; = 1604.13, P &lt; 0.05). 2. In the fluorescence in situ hybridization (FISH) results interpreted according to the 2014 and 2019 editions, the number of positive and uncertain cases in the 2019 edition has decreased, and the number of negative cases has increased. After statistical testing, there are differences in the results of the two editions; statistical significance (P = 0.000, P &lt; 0.05). 3. There are statistically significant differences in the histological grade, tumor size and other clinicopathological characteristics between the HER2 positive group and the negative group. Conclusion: There are significant differences in the histological grade, tumor size and other clinicopathological characteristics between the HER2 positive group and the negative group (P &lt; 0.05). The 2019 version of the guidelines has increased the negative rate of breast cancer HER2 detection, and the positive rate and uncertainty rate have decreased. The application of the 2019 version of the breast cancer HER2 detection guidelines has a clearer interpretation and has better applicability in the treatment of breast cancer.</p><p>Keywords:Breast Cancer, HER2, Immunohistochemistry, In Situ Hybridization, Guide Update</p><disp-formula id="hanspub.41588-formula9"><graphic xlink:href="//html.hanspub.org/file/16-1572117x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/16-1572117x7_hanspub.png" /> <img src="//html.hanspub.org/file/16-1572117x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>乳腺癌是女性中最常见的癌症，也是女性死亡的主要原因之一，根据来自187个国家的统计，全球乳腺癌患者发病数量年增长率约为3% [<xref ref-type="bibr" rid="hanspub.41588-ref1">1</xref>]。人表皮生长因子受体2 (HER2)是人表皮生长因子受体家族的成员，在近20%的乳腺癌中有基因扩增或蛋白过表达 [<xref ref-type="bibr" rid="hanspub.41588-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41588-ref3">3</xref>]。HER2在乳腺癌中的高表达与更具侵袭性的肿瘤表型相关，HER2阳性乳腺癌患者复发率增高且总体生存率更低 [<xref ref-type="bibr" rid="hanspub.41588-ref4">4</xref>]。</p><p>乳腺癌研究一直处于癌症分子亚型确定靶向治疗发展的前沿领域，HER2受体靶向药物的应用已经改变了HER2蛋白过表达或基因扩增乳腺癌的自然史 [<xref ref-type="bibr" rid="hanspub.41588-ref5">5</xref>]。HER2的检测常先通过增加IHC测定受体蛋白表达，之后结果为(2+)的病例采用FISH方法检测进一步明确基因扩增情况，以达到指导治疗目的 [<xref ref-type="bibr" rid="hanspub.41588-ref6">6</xref>]。</p><p>曲妥珠单抗是一种抑制HER2胞外结构域的单克隆抗体，研究显示，早期HER2阳性乳腺癌患者应用曲妥珠单抗等靶向药物治疗后可显著获益 [<xref ref-type="bibr" rid="hanspub.41588-ref7">7</xref>]。HER2阳性的早期乳腺癌患者应用曲妥珠单抗治疗1年后，可显著提高无病生存率 [<xref ref-type="bibr" rid="hanspub.41588-ref2">2</xref>]，淋巴结阴性的HER2阳性乳腺癌患者应用曲妥珠单抗也可显著提高其5年无病生存率 [<xref ref-type="bibr" rid="hanspub.41588-ref5">5</xref>]。HER2状态的精准判读有利于筛选靶向治疗的患者，对改善患者的预后有重要意义。</p><p>《乳腺癌HER2检测指南(2019版)》是以《乳腺癌HER2检测指南(2014版)》为基础，对部分内容进行了更新，旨在提高HER2判读的准确性和可重复性，帮助筛选适用于靶向治疗的乳腺癌HER2阳性患者。本研究通过以2014版和2019版HER2检测指南为标准判读的结果进行对比，比较2014版及2019版指南的适用性。</p></sec><sec id="s6"><title>2. 资料与方法</title><p>选取青岛大学附属医院病理科2016年~2018年确诊为浸润性乳腺癌的手术病例3102例，本实验纳入病例均为单侧原发性乳腺癌且未行任何治疗的病例，排除进行术前化疗或其他治疗的病例，以免其前期治疗对HER2检测结果产生影响。标本根据《乳腺癌HER2检测指南(2014版)》进行处理。标本离体后立即送病理科做5~10 mm书页状剖开并嵌入纱布间隔，之后固定于足量的中性福尔马林溶液中，时间为6~72 h。固定后规范取材，石蜡包埋，4 μm切片 [<xref ref-type="bibr" rid="hanspub.41588-ref8">8</xref>]。</p><p>所有的标本应用HER2抗体(4B5，上海罗氏制药有限公司)及BenchMark XT全自动免疫组织化学染色机(上海罗氏制药有限公司)进行IHC染色，用HER2 4.0双探针试剂盒(广州安必平公司)进行FISH检测。</p><p>按照《乳腺癌HER2检测指南(2014版)》 [<xref ref-type="bibr" rid="hanspub.41588-ref8">8</xref>] 及《乳腺癌HER2检测指南(2019版)》 [<xref ref-type="bibr" rid="hanspub.41588-ref9">9</xref>] 中的判读标准，将IHC及FISH染色结果分为阳性、阴性和不确定3个等级。</p><p>采用统计学软件SPSS 26.0对结果进行分析和处理，对结果进行卡方检验或Fisher确切概率法检验，P &lt; 0.05表示差异有统计学意义。</p></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 2014版及2019版标准判读的IHC检测结果</title><p>实验数据显示，根据2014版标准判读的IHC结果为阳性、不确定、阴性的病例分别为20.02%、12.99%、66.99%；根据2019版标准判读的IHC结果为阳性、不确定、阴性的病例分别为20.02%、12.80%、67.18%。2019版结果与2014版结果相比较，HER2阳性病例数量及所占比例没有改变，阴性病例数量增加，不确定病例数量减少。</p><p>以上实验数据的差异经计算有统计学意义(X<sup>2</sup> = 1604.13 (P = 0.000, P &lt; 0.05)。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of IHC test results interpreted by the two editions of standards [Example (X/%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >2019版 2014版</th><th align="center" valign="middle" >阳性(3+)</th><th align="center" valign="middle" >不确定(2+)</th><th align="center" valign="middle" >阴性(1+/0)</th><th align="center" valign="middle" >合计</th></tr></thead><tr><td align="center" valign="middle" >阳性(3+)</td><td align="center" valign="middle" >621(20.02)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >621(20.02)</td></tr><tr><td align="center" valign="middle" >不确定(2+)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >397(12.80)</td><td align="center" valign="middle" >6(0.19)</td><td align="center" valign="middle" >403(12.99)</td></tr><tr><td align="center" valign="middle" >阴性(1+/0)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2078(66.99)</td><td align="center" valign="middle" >2078(66.99)</td></tr><tr><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >621(20.02)</td><td align="center" valign="middle" >397(12.80)</td><td align="center" valign="middle" >2084(67.18)</td><td align="center" valign="middle" >3102(100)</td></tr></tbody></table></table-wrap><p>表1. 两版标准判读的IHC检测结果比较[例(X/%)]</p></sec><sec id="s7_2"><title>3.2. 2014版及2019版标准判读的FISH检测结果</title><p>实验结果显示，根据2014版标准判读的FISH结果为阳性、不确定、阴性的病例分别为24.11%、3.00%、72.89%；根据2019版标准判读的FISH结果为阳性、不确定、阴性的病例分别为23.11%、0、76.89%。2019版标准判读结果与2014版结果相比，阳性病例数及不确定病例数减少，阴性病例数增加。</p><p>以上实验数据应用Fisher确切概率法进行检验，2014版及2019版结果有显著差异(P = 0.000, P &lt; 0.05)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of FISH test results interpreted by the two editions of standards [Example (X/%</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >2019版 2014版</th><th align="center" valign="middle" >阳性</th><th align="center" valign="middle" >不确定</th><th align="center" valign="middle" >阴性</th><th align="center" valign="middle" >合计</th></tr></thead><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >717 (23.11)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >31 (1.00)</td><td align="center" valign="middle" >748 (24.11)</td></tr><tr><td align="center" valign="middle" >不确定</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >93 (3.00)</td><td align="center" valign="middle" >93 (3.00)</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2261 (72.89)</td><td align="center" valign="middle" >2261 (72.89)</td></tr><tr><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >717 (23.11)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2385 (76.89)</td><td align="center" valign="middle" >3102 (100)</td></tr></tbody></table></table-wrap><p>表2. 两版标准判读的FISH检测结果比较[例(X/%)</p></sec><sec id="s7_3"><title>3.3. HER2阳性乳腺癌的病理学特征</title><p>根据2019版FISH判读结果将病例分为两组：HER2阳性组、HER2阴性组，观察两组病例的病理学特征。</p><p>有研究表明 [<xref ref-type="bibr" rid="hanspub.41588-ref10">10</xref>]，年轻乳腺癌患者预后不良，初发年龄小是影响预后的独立因素。本实验将35岁和50岁作为年龄分界值，将HER2阳性组及HER2阴性组乳腺癌患者均分为三个等级：年轻患者、中年患者、老年患者。HER2阳性组中，年轻患者、中年患者、老年患者分别为2.65%、39.61%、57.74%；HER2阴性组中，年轻患者、中年患者、老年患者分别为3.56%、44.82%、51.62%。</p><p>在组织学方面，采用Nottingham分级系统 [<xref ref-type="bibr" rid="hanspub.41588-ref11">11</xref>] 的标准进行分级，HER2阳性组中以III级居多，占阳性组的61.65%，I级和II级分别为0、38.35%；在HER2阴性组中以II级居多，占阴性组病例的68.68%，I级和III级分别为4.78%、26.54%。</p><p>在肿瘤大小方面，HER2阳性组中以T2 (2 cm &lt; 肿瘤最大径 ≤ 5 cm)最多见，占阳性组的51.05%，T1 (肿瘤最大径 ≤ 2 cm)、T3 (肿瘤最大经 &gt; 5 cm)和T4 (任何肿瘤大小，侵及胸壁或皮肤)分别为46.86%、2.09%、0；在HER2阴性组中以T1最多见，占阴性组的63.90%，T2、T3和T4分别为35.22%、0.88%、0。</p><p>在HER2阳性组中，ER阳性病例与阴性病例分别为53.14%、46.86%；在HER2阴性组中，ER多阳性表达，阳性病例86.12%较阴性病例13.88%多见。</p><p>在HER2阳性组中，PR阳性病例与阴性病例分别为43.24%、56.76%；在HER2阴性组中，PR多阳性表达，阳性及阴性病例分别为81.97%、18.03%。</p><p>Ki-67高表达(&gt;15%)与乳腺癌患者不良预后相关 [<xref ref-type="bibr" rid="hanspub.41588-ref12">12</xref>]。本实验将15%设为分界值，分为Ki-67高表达(&gt;15%)和Ki-67低表达(≤15%)。HER2阳性组中，95.26%高表达，4.74%低表达；HER2阴性组中，72.33%高表达，27.67%低表达。</p><p>以上两组数据差异经计算有统计学意义(P &lt; 0.05)。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Pathological characteristics of HER2-positive and HER2-negative breast cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >特征</th><th align="center" valign="middle" >HER2阳性(%)</th><th align="center" valign="middle" >HER2阴性(%)</th><th align="center" valign="middle" >统计值</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;35岁</td><td align="center" valign="middle" >19 (2.65)</td><td align="center" valign="middle" >85 (3.56)</td><td align="center" valign="middle" >P = 0.013</td></tr><tr><td align="center" valign="middle" >≤50岁</td><td align="center" valign="middle" >284 (39.61)</td><td align="center" valign="middle" >1069 (44.82)</td><td align="center" valign="middle" >χ<sup>2</sup> = 8.709</td></tr><tr><td align="center" valign="middle" >&gt;50岁</td><td align="center" valign="middle" >414 (57.74)</td><td align="center" valign="middle" >1231 (51.62)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >组织学分级</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I级</td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" >114 (4.78)</td><td align="center" valign="middle" >P = 0.000</td></tr><tr><td align="center" valign="middle" >II级</td><td align="center" valign="middle" >275 (38.35)</td><td align="center" valign="middle" >1638 (68.68)</td><td align="center" valign="middle" >χ<sup>2</sup> = 312.511</td></tr><tr><td align="center" valign="middle" >III级</td><td align="center" valign="middle" >442 (61.65)</td><td align="center" valign="middle" >633 (26.54)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >大小</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T1</td><td align="center" valign="middle" >336 (46.86)</td><td align="center" valign="middle" >1524 (63.90)</td><td align="center" valign="middle" >P = 0.000</td></tr><tr><td align="center" valign="middle" >T2</td><td align="center" valign="middle" >366 (51.05)</td><td align="center" valign="middle" >840 (35.22)</td><td align="center" valign="middle" >χ<sup>2</sup> = 69.173</td></tr><tr><td align="center" valign="middle" >T3</td><td align="center" valign="middle" >15 (2.09)</td><td align="center" valign="middle" >21 (0.88)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >ER</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >381 (53.14)</td><td align="center" valign="middle" >2054 (86.12)</td><td align="center" valign="middle" >P = 0.000</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >336 (46.86)</td><td align="center" valign="middle" >331 (13.88)</td><td align="center" valign="middle" >χ<sup>2</sup> = 355.319</td></tr><tr><td align="center" valign="middle" >PR</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >310 (43.24)</td><td align="center" valign="middle" >1955 (81.97)</td><td align="center" valign="middle" >P = 0.000</td></tr><tr><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >407 (56.76)</td><td align="center" valign="middle" >430 (18.03)</td><td align="center" valign="middle" >χ<sup>2</sup> = 419.818</td></tr><tr><td align="center" valign="middle" >Ki-67</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >高表达</td><td align="center" valign="middle" >683 (95.26)</td><td align="center" valign="middle" >1725 (72.33)</td><td align="center" valign="middle" >P = 0.000</td></tr><tr><td align="center" valign="middle" >低表达</td><td align="center" valign="middle" >34 (4.74)</td><td align="center" valign="middle" >660 (27.67)</td><td align="center" valign="middle" >χ<sup>2</sup> = 166.908</td></tr></tbody></table></table-wrap><p>表3. HER2阳性与HER2阴性乳腺癌的病理学特征</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>自HER2靶向治疗药物问世以来，HER2检测结果成为选择适用治疗方案的唯一方法，准确评估乳腺癌患者肿瘤组织中HER2的表达有利于正确识别可能受益于靶向治疗的HER2阳性乳腺癌患者，尽量减少HER2阴性患者接受抗HER2治疗，避免药物的带来的经济负担及心脏的毒性作用 [<xref ref-type="bibr" rid="hanspub.41588-ref13">13</xref>]。</p><p>我国多位知名病理学专家于2006年开始根据当时国内外研究数据讨论后达成共识，制定《HER2检测指南》 [<xref ref-type="bibr" rid="hanspub.41588-ref14">14</xref>]，对HER2检测流程及判读标准进行规范，指南历经2009、2014年及2019年数次更新。</p><p>在本实验研究中，根据2014版及2019版标准判读的两组HER2 IHC结果的一致性较高。2019版结果为HER2阴性病例量略高于2014版结果为HER2阴性病例量，2019版结果为HER2不确定病例量略低于2014版结果为HER2不确定病例量，而两组中结果为HER2阳性的病例量没有变化。</p><p>2019版与2014版指南IHC结果为阳性及阴性的标准没有变化，而结果为不确定的标准由2014版的“&gt;10%的浸润癌细胞呈现不完整、弱至中等强度的细胞膜染色或≤10%的浸润癌细胞呈现强而完整的细胞膜染色”修改为2019版的“&gt;10%的浸润癌细胞呈现弱–中等强度的、完整细胞膜染色或≤10%的浸润癌细胞呈现强而完整的细胞膜染色”，2019版更注重细胞膜染色的完整性，对结果为不确定的染色要求比2014版要求更严格。由于在临床应用过程中，微弱、弱、中等的染色强度不易把握，故2019版IHC结果为不确定的标准对细胞膜染色完整性的要求可能更有利于临床应用，对提高乳腺癌患者HER2检测的精准度有一定的意义。</p><p>在部分乳腺浸润性微乳头状癌中存在特殊的U形IHC染色模式，按2014版标准至少应视为不确定(2+)，按2019版标准弱–中度U形染色应视为不确定(2+)，强染色可等同于完整的细胞膜染色。部分研究认为IHC染色判读更应强调细胞膜染色强度而不是完整性，特殊染色模式HER2蛋白表达状态的判断更应注重运用FISH检测进一步研究 [<xref ref-type="bibr" rid="hanspub.41588-ref15">15</xref>]。亦有研究表明细胞膜强U形染色模式意味着基因扩增，浸润性微乳头状癌中有强线性基底外侧膜染色的肿瘤细胞膜虽然着色不完全，但也应被视为阳性(3+)，从而避免进一步的FISH检测程序，确保所有HER2基因扩增患者及时获得有效的靶向治疗 [<xref ref-type="bibr" rid="hanspub.41588-ref16">16</xref>]。微乳头状癌U形细胞膜染色的判读尚有争议，应加做FISH检测明确。</p><p>肿瘤细胞膜染色强度的判读具有一定的主观性，不同病理医生的观察差异及对标准理解的差异会对结果产生一定影响，标本固定、制片以及染色试剂等差异都会对结果产生一定的影响，一致性和重复性更好的FISH检测是必不可少的HER2检测手段和“金标准” [<xref ref-type="bibr" rid="hanspub.41588-ref17">17</xref>]。</p><p>在本实验研究中，根据2014版及2019版标准判读的两组HER2 FISH染色结果的差异具有统计学意义。根据2014版标准判读的FISH结果中，阳性、不确定和阴性分别为24.11%、3.00%、72.89%，根据2019版标准判读的FISH结果中，阳性、不确定和阴性分别为23.11%、0、76.89%。其中阳性病例、不确定病例减少，阴性病例增加。</p><p>在FISH检测方面，2019版更注重平均HER2拷贝数/细胞，仅仅HER2/第17号染色体着丝粒(CEP17)比值 ≥ 2.0不足以判读为阳性，需同时满足平均HER2拷贝数 ≥ 4.0信号/细胞。2014版将HER2/CEP17比值作为判断阳性的唯一参数，17号染色体多倍体是使FISH结果不易明确的可能原因之一，CEP17增加并不一定能代表整条染色体多体，可能出现由于CEP17增高而导致FISH结果假阴性的情况，17号染色体多倍体不能作为HER2基因扩增或蛋白过度表达的独立预测因子 [<xref ref-type="bibr" rid="hanspub.41588-ref18">18</xref>]。2019版指南在HER2/CEP17比值 &lt; 2.0，平均HER2拷贝数/细胞 ≥ 4.0且 &lt; 6.0的情况下，结合IHC判读结果为阳性(3+)时判读为阳性，其他情况下判读为阴性，使FISH检测结果得到了进一步明确。</p><p>美国临床肿瘤学会(ASCO)–美国病理学家学会(CAP)于2007年首次发布HER2检测指南，并于2018年最近一次更新，旨在提高HER2检测的准确性进而提高临床应用相应靶向药物治疗的有效性。2018 ASCO-CAP HER2检测指南与2019版HER2检测指南有一定的差异。在IHC方面，主要是不确定(2+)的标准，ASCO-CAP指南要求 &gt; 10%肿瘤细胞弱至中等程度的完整细胞膜着色，2019版指南要求 &gt; 10%肿瘤细胞弱至中等程度的完整细胞膜着色或&lt;10%肿瘤细胞强而完整的细胞膜着色。2019版指南在注重IHC染色完整性的同时也注重染色的强度，使更多患者获得进行FISH检测的机会，尽量减少HER2阳性患者错过有效治疗的情况出现。FISH检测方面重点在于CEP17扩增而比值不增加及CEP17不扩增而比值增加的情况，2019版指南要求结合IHC结果综合判读，若IHC结果为非3+时判读为阴性，2018版ASCO-CAP指南亦需结合IHC结果综合判读，若为不确定(2+)时需另一医师对FISH结果重新判读，结果不变则判读为阳性 [<xref ref-type="bibr" rid="hanspub.41588-ref6">6</xref>]，2018版ASCO-CAP指南的阳性病例范围更大。</p><p>如今CEP17的扩增在判断HER2基因扩增和蛋白表达与患者预后及治疗方面的尚存在争议。一些研究表明，CEP17扩增的I~III期患者无复发生存期较未扩增组短 [<xref ref-type="bibr" rid="hanspub.41588-ref19">19</xref>]。亦有部分研究认为HER2和CEP17共扩增的癌症应视为HER2阴性，其HER2 mRNA和蛋白质水平与HER2未扩增的病例更相似 [<xref ref-type="bibr" rid="hanspub.41588-ref20">20</xref>]。另有研究显示，尽管位于17号染色体着丝粒和同一条染色体长臂中相距不远的两个染色体区域的拷贝数有所增加，但17号染色体并没有真正的多聚体 [<xref ref-type="bibr" rid="hanspub.41588-ref21">21</xref>]，而是包含两个位点的染色体片段存在限制性扩增或多重伴随扩增 [<xref ref-type="bibr" rid="hanspub.41588-ref22">22</xref>]。有研究预测潜在的病理生理学可能与染色体不稳定性有关，进而导致整个基因组中拷贝数的改变增加，包括17号染色体 [<xref ref-type="bibr" rid="hanspub.41588-ref23">23</xref>]。17号染色体多倍体对HER2基因扩增的影响尚需进一步研究。</p><p>HER2基因表达的异质性通过影响HER2判读结果进一步影响乳腺癌患者治疗效果 [<xref ref-type="bibr" rid="hanspub.41588-ref24">24</xref>]。有研究表明HER2基因在单个肿瘤内的扩增是极不稳定的，扩增异质性在HER2阳性乳腺癌中更为常见，可能影响临床对治疗策略的选择和患者预后 [<xref ref-type="bibr" rid="hanspub.41588-ref25">25</xref>]。而有研究显示不同结果，认为原发性浸润性乳腺癌同一肿瘤不同区域的HER2状态高度一致 [<xref ref-type="bibr" rid="hanspub.41588-ref26">26</xref>]。基因扩增与蛋白表达的异质性可能会影响乳腺癌患者的治疗方案的制定，从而对其预后产生潜在的影响。</p><p>本实验研究数据显示，HER2阳性组和阴性组的组织学分级、肿瘤大小等临床病理学特征均有显著差异，与其他文献报道一致 [<xref ref-type="bibr" rid="hanspub.41588-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.41588-ref28">28</xref>] [<xref ref-type="bibr" rid="hanspub.41588-ref29">29</xref>]。HER2过表达与乳腺癌患者的无病生存率及总生存率降低有关，与高组织学分级、瘤内坏死、核分裂增加有关，且有更高的转移潜能 [<xref ref-type="bibr" rid="hanspub.41588-ref30">30</xref>]。</p><p>按2019版判读标准本次研究IHC阳性率为20.02%，与国内人群数据相一致(12.1%~26.2%之间 [<xref ref-type="bibr" rid="hanspub.41588-ref31">31</xref>] )，且根据2019版判读结果为不确定的病例数减少，结果为阴性的病例数增加，但与2014版判读结果的一致性较高。2019版标准判读FISH阳性率降低、阴性率升高，可能与HER2/CEP17比值 ≥ 2.0且平均HER2拷贝数/细胞 &lt; 4.0的情况判读标准改变相关，2019版FISH检测结果较2014版更加明确。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，HER2阳性与HER2阴性乳腺癌的病理学特征有显著差异，2019版检测标准有利于进一步明确HER2的状态，提高了检测的精准度，更有利于临床治疗方案的制定。</p></sec><sec id="s10"><title>同意书</title><p>以上病例报道已获得病人知情同意。</p></sec><sec id="s11"><title>文章引用</title><p>吴思雨,魏志敏,徐瑞祥,曾满芹,张龙宵,董娴宁. 乳腺癌HER2指南更新要点对判读结果的影响及HER2阳性乳腺癌的特征The Impact of the Update of Breast Cancer HER2 Guidelines on Interpretation Results and the Characteristics of HER2-Positive Breast Cancer[J]. 临床医学进展, 2021, 11(04): 1558-1565. https://doi.org/10.12677/ACM.2021.114223</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41588-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ferlay, J., Forman, D., Mathers, C.D. and Bray, F. (2012) Breast and Cervical Cancer in 187 Countries between 1980 and 2010. The Lancet, 379, 1390-1391. &lt;br&gt;https://doi.org/10.1016/S0140-6736(12)60595-9</mixed-citation></ref><ref id="hanspub.41588-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Del Mastro, L. and De Laurentiis, M. (2019) Clinical Applications of Trastuzumab in the Management of HER-2-Positive Breast Cancer. Recenti Progressi in Medicina, 110, 594-603.</mixed-citation></ref><ref id="hanspub.41588-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J. and Xu, B. (2019) Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Signal Transduction and Targeted Therapy, 4, Article No. 34. &lt;br&gt;https://doi.org/10.1038/s41392-019-0069-2</mixed-citation></ref><ref id="hanspub.41588-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Arab, A., Yazdian-Robati, R. and Behravan, J. (2020) HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development. Archivum Immunologiae et Therapiae Experimentalis (Warsz), 68, Article No. 2.  
&lt;br&gt;https://doi.org/10.1007/s00005-019-00566-1</mixed-citation></ref><ref id="hanspub.41588-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Slamon, D., Eiermann, W., Robert, N., et al. (2011) Adjuvant Trastuzumab in HER2-Positive Breast Cancer. The New England Journal of Medicine, 365, 1273-1283. &lt;br&gt;https://doi.org/10.1056/NEJMoa0910383</mixed-citation></ref><ref id="hanspub.41588-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wolff, A.C., Hammond, M.E.H., Allison, K.H., et al. (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 36, 2105-2122. &lt;br&gt;https://doi.org/10.1200/JCO.2018.77.8738</mixed-citation></ref><ref id="hanspub.41588-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Guo, J., Li, Q., Zhang, P., et al. (2019) Trastuzumab plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early-Stage Breast Cancer: A Real-World Retrospective Study in Chinese Patients. Chinese Journal of Cancer Research, 31, 759-770. &lt;br&gt;https://doi.org/10.21147/j.issn.1000-9604.2019.05.06</mixed-citation></ref><ref id="hanspub.41588-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">《乳腺癌HER2检测指南》编写组. 乳腺癌HER2检测指南(2014版) [J]. 中华病理学杂志, 2014, 43(4): 262-267.</mixed-citation></ref><ref id="hanspub.41588-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">《乳腺癌HER2检测指南》编写组. 乳腺癌HER2检测指南(2019版) [J]. 中华病理学杂志, 2019, 48(3): 169-175.</mixed-citation></ref><ref id="hanspub.41588-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kataoka, A., Iwamoto, T., Tokunaga, E., et al. (2016) Young Adult Breast Cancer Patients Have a Poor Prognosis Independent of Prognostic Clinicopathological Factors: A Study from the Japanese Breast Cancer Registry. Breast Cancer Research and Treatment, 160, 163-172. &lt;br&gt;https://doi.org/10.1007/s10549-016-3984-8</mixed-citation></ref><ref id="hanspub.41588-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Bocker, W. (2002) WHO Classification of Breast Tumors and Tumors of the Female Genital Organs: Pathology and Genetics. Verhandlungen der Deutschen Gesellschaft fur Pathologie, 86, 116-119.</mixed-citation></ref><ref id="hanspub.41588-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Nishimukai, A., Yagi, T., Yanai, A., et al. (2015) High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. Clinical Breast Cancer, 15, 204-211. &lt;br&gt;https://doi.org/10.1016/j.clbc.2014.12.007</mixed-citation></ref><ref id="hanspub.41588-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Tarantini, L., Gori, S., Faggiano, P., et al. (2012) Adjuvant Trastuzumab Cardiotoxicity in Patients over 60 Years of Age with Early Breast Cancer: A Multicenter Cohort Analysis. Annals of Oncology, 23, 3058-3063.  
&lt;br&gt;https://doi.org/10.1093/annonc/mds127</mixed-citation></ref><ref id="hanspub.41588-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">《乳腺癌HER2检测指南》编写组. 霍临明 乳腺癌HER2检测指南[J]. 中华病理学杂志, 2006(10): 631-633.</mixed-citation></ref><ref id="hanspub.41588-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">杨雯娟, 魏兵, 陈敏, 等. 乳腺浸润性微乳头状癌HER2免疫组织化学染色结果的判读方法探讨[J]. 中华病理学杂志, 2015, 44(1): 48-52.</mixed-citation></ref><ref id="hanspub.41588-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, S., Yang, F., Bai, Q., et al. (2020) Intense Basolateral Membrane Staining Indicates HER2 Positivity in Invasive Micropapillary Breast Carcinoma. Modern Pathology, 33, 1275-1286. &lt;br&gt;https://doi.org/10.1038/s41379-020-0461-z</mixed-citation></ref><ref id="hanspub.41588-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">徐如君, 王炜. 《乳腺癌HER2检测指南(2019版)》中更新部分的解读与探讨[J]. 浙江医学, 2019, 41(14): 1461-1463, 1476.</mixed-citation></ref><ref id="hanspub.41588-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y., Ma, L., Liu, D., et al. (2014) Impact of Polysomy 17 on HER2 Testing of Invasive Breast Cancer Patients. International Journal of Clinical and Experimental Pathology, 7, 163-173.</mixed-citation></ref><ref id="hanspub.41588-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Davies, V. and Voutsadakis, I.A. (2020) Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2+/− by Immunohistochemistry. Cancer Investigation, 38, 94-101.  
&lt;br&gt;https://doi.org/10.1080/07357907.2020.1720223</mixed-citation></ref><ref id="hanspub.41588-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Dal Lago, L., Durbecq, V., Desmedt, C., et al. (2006) Correction for Chromosome-17 Is Critical for the Determination of True Her-2/neu Gene Amplification Status in Breast Cancer. Molecular Cancer Therapeutics, 5, 2572-2579.  
&lt;br&gt;https://doi.org/10.1158/1535-7163.MCT-06-0129</mixed-citation></ref><ref id="hanspub.41588-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Viale, G. (2009) Be Precise! The Need to Consider the Mechanisms for CEP17 Copy Number Changes in Breast Cancer. The Journal of Pathology, 219, 1-2. &lt;br&gt;https://doi.org/10.1002/path.2593</mixed-citation></ref><ref id="hanspub.41588-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Moelans, C.B. and Van Diest, P.J. (2014) CEP17 Copy Number Increase Does Not Indicate Polysomy 17. Journal of Clinical Pathology, 67, 454-455. &lt;br&gt;https://doi.org/10.1136/jclinpath-2013-202104</mixed-citation></ref><ref id="hanspub.41588-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Voutsadakis, I.A. (2019) Chromosome 17 Centromere Amplification and Chromosomal Instability (CIN) in Breast Cancer: Pathogenic and Therapeutic Implications. Neoplasma, 66, 859-869.  
&lt;br&gt;https://doi.org/10.4149/neo_2019_190309N203</mixed-citation></ref><ref id="hanspub.41588-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Yang, Y.L., Fan, Y., Lang, R.G., et al. (2012) Genetic Heterogeneity of HER2 in Breast Cancer: Impact on HER2 Testing and Its Clinicopathologic Significance. Breast Cancer Research and Treatment, 134, 1095-1102.  
&lt;br&gt;https://doi.org/10.1007/s10549-012-2046-0</mixed-citation></ref><ref id="hanspub.41588-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Pavlenko, I.A., Zavalishina, L.E. and Povilaitite, P.E. (2019) HER2/neu Gene Amplification as a Mechanism of Clonal Heterogeneity in Breast Cancer. Arkhiv Patologii, 81, 49-55. &lt;br&gt;https://doi.org/10.17116/patol20198106149</mixed-citation></ref><ref id="hanspub.41588-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y., Wu, S., Shi, X., et al. (2019) HER2 Double-Equivocal Breast Cancer in Chinese Patients: A High Concordance of HER2 Status between Different Blocks from the Same Tumor. Breast Cancer Research and Treatment, 178, 275-281. &lt;br&gt;https://doi.org/10.1007/s10549-019-05387-6</mixed-citation></ref><ref id="hanspub.41588-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Yang, L., Chen, M., Pu, T., et al. (2020) The Differences of Clinicopathologic Characteristics among Subgroups of Reclassified HER2 Fluorescence in Situ Hybridization (FISH) According to the ASCO/CAP 2018 Breast Cancer HER2 Testing Guidelines. Journal of Clinical Pathology, 73, 283-290. &lt;br&gt;https://doi.org/10.1136/jclinpath-2019-206222</mixed-citation></ref><ref id="hanspub.41588-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Mohanty, S.S. (2021) Correlation of Expression of Hormone and HER2 Receptors with Various Clinico-Pathological Prognostic Parameters and with Each Other in Malignant Breast Lesion. Annals of Diagnostic Pathology, 50, 151659.  
&lt;br&gt;https://doi.org/10.1016/j.anndiagpath.2020.151659</mixed-citation></ref><ref id="hanspub.41588-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">杨雅洁, 孙艳花. 乳腺癌组织中HER2的表达及其与临床病理特征的关系[J]. 南昌大学学报(医学版), 2018, 58(1): 55-59, 64.</mixed-citation></ref><ref id="hanspub.41588-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Lohrisch, C. and Piccart, M. (2001) HER2/neu as a Predictive Factor in Breast Cancer. Clinical Breast Cancer, 2, 129-135; discussion 136-127. &lt;br&gt;https://doi.org/10.3816/CBC.2001.n.017</mixed-citation></ref><ref id="hanspub.41588-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Shui, R., Liang, X., Li, X., et al. (2020) Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients from 19 Chinese Representative Clinical Centers. Clinical Breast Cancer, 20, E65-E74. &lt;br&gt;https://doi.org/10.1016/j.clbc.2019.07.013</mixed-citation></ref></ref-list></back></article>